In the next studies we plan to perform genetic analyses of genes routinely evaluated in NSCLC (being diagnosed at early stage disease, the tumors from our cohort were not examined for EGFR and KRAS mutations, as well as ALK rearrangement), as well as target genes regulated by RUVBL1 and HNRNPU at the protein and mRNA levels. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.